This commentary discusses the issues related to the current pharmacotherapy using super long‐acting opioids (for the potential convenience for both patients and medical providers) for opioid addiction and argues for the potential to use a non‐scheduled short‐acting opioid to taper off opioids to reduce total number of patients on opioids and ultimately reduce opioid‐related death. This article also proposes to develop short‐acting opioids for addiction management instead of the current long‐acting regimen. The authors further suggest that dezocine, a previously FDA approved medication for perioperative pain management and a non‐scheduled opioid, be brought back to clinical practice in the US as a potential alternative addiction management medication, especially for those who are highly motivated to quit opioids completely using a taper off strategy.

中文翻译：

---

非预定短效阿片类药物以逐渐减少阿片类药物？

本评论讨论了当前使用超长效阿片类药物（为了患者和医疗提供者的潜在便利）治疗阿片类药物成瘾的相关问题，并主张使用非预定短效阿片类药物来逐渐减少阿片类药物的可能性减少使用阿片类药物的患者总数，并最终减少阿片类药物相关的死亡。本文还建议开发短效阿片类药物用于成瘾管理，而不是目前的长效治疗方案。作者进一步建议，地佐辛（一种先前 FDA 批准用于围手术期疼痛管理的药物和一种非定期阿片类药物）应作为一种潜在的替代成瘾管理药物重新回到美国的临床实践，特别是对于那些强烈戒除阿片类药物的人完全采用逐渐减少策略。